Stoke Therapeutics (STOK) Other Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 27.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 27.68% YoY), while the FY2025 annual figure was $1.1 million, up 40.77% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.5 million, up from $1.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.1 million in Q1 2025, with the low at $426000.0 in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $753000.0 (2024), against an average of $899529.4.
• Peak annual rise in Other Accumulated Expenses reached 1421.43% in 2022, while the deepest fall reached 55.15% in 2022.
• Stoke Therapeutics' Other Accumulated Expenses stood at $509000.0 in 2022, then surged by 68.37% to $857000.0 in 2023, then slipped by 12.14% to $753000.0 in 2024, then jumped by 40.77% to $1.1 million in 2025, then jumped by 41.51% to $1.5 million in 2026.
• Business Quant data shows STOK's Other Accumulated Expenses at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $795000.0 in Q3 2025.